Three hundred thousand patients. For SciBase, the Swedish medical device maker, that figure represents nearly a decade of methodical work convincing dermatologists to measure electrical signals in suspicious moles. It's the kind of milestone that sounds impressive in a press release—and for a company that's burned through capital trying to commercialize technology born in a Karolinska Institute lab, it matters. But the real question hanging over SciBase's latest hardware refresh isn't whether Nevisense works. It's whether American dermatology practices will ever pay for it.
The timing is curious. This April, as SciBase unveiled Nevisense V—complete with a 12-inch touchscreen, crisper display, and the sort of interface upgrades that suggest someone finally asked a UX designer for input—the company finds itself at an inflection point it's been approaching for years. Germany has become a revenue engine, with "multiple hundreds" of systems installed and a steady stream of disposable electrode sales. The US market, despite FDA premarket approval secured back in 2017, remains stubbornly elusive. And that divergence tells you nearly everything about the economics of diagnostic innovation in 2025.
When Physics Meets Pattern Recognition
The core technology is elegant in theory. Place a disposable electrode on a lesion. Apply saline solution. Measure electrical impedance—tissue's resistance to alternating current—at roughly 700 data points across frequencies ranging from 1 kHz to 2.5 MHz. Feed that electrical signature into an algorithm trained on thousands of lesions, and within three to five minutes, the device spits out a score from 0 to 10.
Anything below 4? Negative. Four and above? Time to consider a biopsy, because the lesion carries elevated melanoma risk.
The appeal for clinicians is straightforward: a quantitative data point to supplement visual inspection and dermoscopy. The challenge is what happens when you look closely at the pivotal trial data. Published in the British Journal of Dermatology in 2014, that 2,416-lesion study showed Nevisense hitting 96.6% sensitivity—excellent for ruling out cancer—with a negative predictive value of 98.2%. But specificity? Just 34.4%.
Translation: Nevisense will flag benign lesions as suspicious more than two-thirds of the time.
SciBase's response has remained consistent over the years. Missing a melanoma, the company argues, carries far graver consequences than ordering an unnecessary biopsy. It's a reasonable clinical position. Whether it's a commercially viable one depends on whether dermatologists view that trade-off as acceptable—and whether payers agree to reimburse a test that generates that many false positives.
The Reimbursement Maze
Here's where the story gets complicated. Germany's medical system, with its willingness to adopt novel technologies and relatively streamlined approval pathways, gave SciBase room to build a commercial operation. When Germany's S1 imaging guideline listed micro-electrical impedance spectroscopy as "valuable decision-making technology" this past January—citing equipment prices starting around €6,900—it provided validation that helped drive installations.
The US operates differently. Category III CPT codes (0658T-0659T), assigned in July 2021, acknowledge that electrical impedance spectroscopy for skin lesions exists as a billable procedure. But Category III codes don't guarantee coverage. They're essentially placeholder codes that say: "This is a thing doctors are doing, and we've documented it." Whether Medicare or private insurers pay for it? That's another matter entirely.
So SciBase has pursued partnerships with large dermatology groups—Advanced Dermatology & Cosmetic Surgery in 2020, Schweiger Dermatology Group's New Jersey pilot in 2023, Palm Beach Dermatology's six-system order last July. A Mayo Clinic pilot launched early this year to evaluate how Nevisense fits into digital workflows. These are serious organizations. But pilot programs and initial orders aren't the same as widespread adoption.
The self-pay program SciBase launched in June 2025 acknowledges the economic reality. Practices can't wait indefinitely for reimbursement clarity. Patients willing to pay out-of-pocket provide a revenue bridge, but it's hardly a scalable strategy for a platform that requires ongoing electrode purchases to generate recurring revenue.
Compare that to DermTech, which secured a Category I CPT code (0089U) for its genomic adhesive-patch test—and coverage from some payers. Or consider reflectance confocal microscopy systems like VivaScope, which landed Category I codes and reimbursement for certain configurations. Those precedents show it's possible to crack the US market. SciBase just hasn't managed it yet.
Beyond Melanoma: The Skin Barrier Pivot
Perhaps recognizing the melanoma market's limitations, SciBase has been exploring adjacent applications. The same impedance measurements that flag malignant tissue can apparently assess skin barrier integrity—a metric relevant in cosmetic research and atopic dermatitis studies.
In May 2024, the company launched eBarrier Score, positioning it for research applications rather than clinical diagnostics. The National Institutes of Health bought a system that September for microbiome work. By February of this year, SciBase was announcing it could predict atopic dermatitis in newborns, with data slated for presentation at an American Academy of Allergy, Asthma & Immunology meeting.
Those research threads converged commercially through Castle Biosciences, which invested approximately SEK 19 million in June 2025 and later extended a SEK 20 million loan. Castle licensed the electrical impedance platform to develop tests for dermatologic conditions, starting with predicting atopic dermatitis flares. An initial clinical study order—for Nevisense Go, a portable pen-sized variant, plus electrodes—totaled roughly $800,000 last September.
Nevisense Go represents a strategic bet that miniaturizing the hardware opens new markets. A November 2022 collaboration with Johnson & Johnson Consumer targeted an AI screening tool for infant skin barrier dysfunction using the portable device. Whether these ventures generate meaningful revenue remains unclear. But they suggest SciBase recognizes it needs multiple revenue streams if the melanoma market proves too narrow.
A Crowded, Contentious Landscape
SciBase doesn't operate in a vacuum. DermaSensor, which secured FDA clearance in January 2024, uses elastic scattering spectroscopy to detect all three major skin cancers—melanoma, basal cell, squamous cell. Its pivotal data showed 96% sensitivity and 97% negative predictive value, and it's marketed to primary care physicians who may lack dermoscopy training. That's a different positioning than Nevisense, which FDA cleared as an adjunct to help dermatologists decide on biopsies.
DermTech's genomic approach—adhesive patches collecting surface cells for genetic marker analysis—claims a 99% negative predictive value. The company frames its test as complementary to visual assessment, a rule-out strategy to reduce unnecessary biopsies.
Then there's the cautionary tale of MelaFind, a multispectral imaging device that once competed in this space but has since been discontinued. Low specificity, reimbursement challenges, workflow friction—it all added up to commercial failure. Even with FDA approval.
An FDA advisory panel in July 2022 urged stringent evaluation standards for AI-powered skin lesion analyzers, citing risks of false negatives and positives. SciBase publicly supported maintaining the Class III PMA pathway, a stance that favors companies with existing approvals over newer apps with lighter evidence packages. That regulatory position may protect SciBase's moat in the near term. But it also highlights how uncertain this market remains.
The Endurance Test
Eight years after FDA approval, SciBase has staying power—something not every medtech startup can claim. The 300,000-patient milestone proves the technology works in clinical settings. The German market provides real revenue. The Nevisense V hardware refresh shows the company is still investing in the platform.
But staying power isn't the same as breakthrough success. The question facing SciBase is whether a device with 34% specificity—even paired with 96% sensitivity—can convince US payers that its clinical value justifies coverage. Whether the skin barrier research pivot generates material revenue. Whether the portable Nevisense Go finds product-market fit beyond research labs.
The company has been walking this tightrope for years. Multiple revenue streams, slow partnerships, pilot programs that may or may not scale. It's a strategy that's kept SciBase alive. Whether it's enough to turn electrical impedance spectroscopy into routine dermatology practice—or whether this remains a niche diagnostic tool propped up by one European market—depends on battles that have little to do with the elegance of the underlying physics.
Sometimes the hardest part of innovation isn't building the technology. It's convincing the system to pay for it.
